Search Results: (30 results)

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation. The study involves people with Li-Fraumeni syndrome and people from families with Li-Fraumeni syndrome filling out questionnaires with their medical information.

Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor. The study will create a registry of women at high risk of breast cancer. A registry collects data about specific populations to understand them better. This study will also look at whether an abbreviated MRI works as well as a full MRI for screening women at high risk of breast cancer.

This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

We are talking with African American adults about cancer genetic testing, including those that have received a positive cancer genetic testing result and people with a family member who received testing. We are learning about new and improved ways to support African American individuals and families before, during and after they participate in cancer genetic testing.

Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis. this study to evaluate an online tool developed to educate and provide support to women and people assigned female at birth who are interested in family building after cancer. This study involves the completion of four online surveys. All study procedures are done remotely.

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.

This study will test the safety and effectiveness of the drug sovilnesib in patients with ovarian cancer.

The purpose of this study is to get participants’ opinions on the content, format, and design of educational materials that inform about the emotional consequences of undergoing a bilateral mastectomy.

Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC). This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance. 

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

• For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.
• People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.

Survey for cancer caregivers of an LGBTQIA+ family member or friend to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors when compared to standard of care symptom management. 

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for colorectal, pancreatic or prostate cancer. You can take the survey here. 

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer. The study will test ways of teaching participants about breast cancer and risk factors, comparing the current standard of care to new personal educational sessions. Bilingual and bicultural staff are available for the phone study to make the study open to both English and Spanish speakers.

Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.

This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.

This study seeks to interview individuals who come from families with high cancer risk and/or who have tested positive for a BRCA1 or BRCA2 genetic mutation. We are also interested in individuals who may be contemplating BRCA 1/2 genetic testing; those who feel they lack access to genetic testing or who feel they lack information and social and medical support with regard to getting access to genetic testing; those who have been diagnosed with breast cancer who may be at high risk for a range of hereditary cancer. We are especially hoping to reach racially and ethnically diverse males and females whose experiences are often left out of research studies.

Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.